Skip to main content

Table 2 Blood Transfusion and Chelation Therapy Data of the Study Population

From: CMV, B and C hepatitis among multi-transfused hereditary hemolytic Anemia children: an updated Egyptian experience

Transfusion and Chelation Variables Data
Disease duration (years)
 - Mean (SD) 8.1 (±4.9)
 - Range 1–17
Age at 1st blood transfusion (years)
 - Mean (SD) 1.5 (±1.5)
 - Range 0.5–9
Blood transfusion duration (years)
 - Mean (SD) 8.04 (±4.94)
 - Range 1–17
RBC Transfusion Index (ml/kg/year)
 - Mean (SD) 183.14 (±48.5)
 - Range 30–360
Transfusion frequency (times/year)
 - Mean (SD) 12 (±6)
 - Range 4–20
Type of chelation No (%)
 - Deferasirox 204 (42.8)
 - Deferiprone 93 (19.5)
 - Desferoxamin 58 (12.2)
 - Combination) Deferasirox/Desferoxamine( 72 (15.1)
 - None 50 (10.5)
Compliance No (%)
 - Compliant 149 (35)
 -Noncompliant 278 (65)
Chelation duration (years)
 - Mean (SD) 7.2 (±4.6)
 - Range 0.5–17
  1. RBC’s Red Blood Cells, No Number, SD standard deviation